Sensei Biotherapeutics (FTH) to Post Quarterly Earnings on Tuesday

Sensei Biotherapeutics (NASDAQ:FTH) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Sensei Biotherapeutics to announce earnings of ($5.0450) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:30 AM ET.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, analysts expect Sensei Biotherapeutics to post $-17 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sensei Biotherapeutics Stock Performance

FTH opened at $27.24 on Friday. The stock has a market capitalization of $36.50 million, a PE ratio of -0.19 and a beta of -0.26. Sensei Biotherapeutics has a twelve month low of $7.10 and a twelve month high of $37.90.

Analyst Upgrades and Downgrades

FTH has been the topic of a number of recent analyst reports. Leerink Partners started coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Oppenheimer assumed coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Raymond James Financial initiated coverage on Sensei Biotherapeutics in a research report on Friday. They set an “outperform” rating and a $56.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $54.89.

Insider Buying and Selling

In related news, CFO Brian C. Stephenson acquired 9,391 shares of the stock in a transaction on Wednesday, June 24th. The stock was purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the transaction, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. The trade was a 53.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. The trade was a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 49,494 shares of company stock worth $1,188,822 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 10.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.